FDA clears Algotec's MediSurf

Article

Algotec of Raanana, Israel, has received Food and Drug Administration 510(k) clearance for its MediSurf software, a product for distributing medical images and clinical data over the Internet and intranets. Shipments have already begun via a worldwide

Algotec of Raanana, Israel, has received Food and Drug Administration 510(k) clearance for its MediSurf software, a product for distributing medical images and clinical data over the Internet and intranets. Shipments have already begun via a worldwide OEM relationship with Elscint.

MediSurf users employ a standard World Wide Web browser and applets based on the Java programming language developed by Sun Microsystems. The browser is used to access the MediSurf DICOM 3.0-compliant server, which is linked to both clinical image and data sources. There is no need for installation of additional hardware or software at end-user sites, according to the company.

Algotec debuted MediSurf at last year's Radiological Society of North America meeting (SCAN Special Report 12/96). In addition to three beta sites in the U.S., Canada, and Germany, MediSurf has been installed at nine other institutions. Two MediSurf packages have been installed in the U.S.

Initially, Algotec will market MediSurf in the U.S. through OEMs. In a few months, however, the firm will sell MediSurf via regional distributors as well as through direct sales in some cases, said Kobi Margolin, Algotec marketing manager. Because the company expects OEMs to contribute most of MediSurf's sales, Algotec is actively looking for OEM relationships in addition to the Elscint agreement, Margolin said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.